Additional file 1 of Combined inhibition of ribonucleotide reductase and WEE1 induces synergistic anticancer activity in Ewing’s sarcoma cells

Additional file S1: Table S1: CI values for triapine plus adavosertib in WE-68 cells. Based on data from Fig. 1A, CI values were calculated with the Chou-Talalay method. CI values in bold indicate a synergistic interaction. Additional file S2: Table S2: CI values for triapine plus adavosertib in SK-ES-1 cells. Based on data from Fig. 1A, CI values were calculated with the Chou-Talalay method. CI values in bold indicate a synergistic interaction (CI values > 0.8 were not considered synergistic). Additional file S3: Table S3: CI values for triapine plus adavosertib in A673 cells. Based on data from Fig. 1A, CI values were calculated with the Chou-Talalay method. CI values in bold indicate a synergistic interaction (CI values > 0.8 were not considered synergistic). Additional file S4: Table S4: CI values for triapine plus ZN-c3 in WE-68 cells. Based on data from Fig. 1B, CI values were calculated with the Chou-Talalay method. CI values in bold indicate a synergistic interaction (CI values > 0.8 were not considered synergistic). Additional file S5: Table S5: CI values for triapine plus ZN-c3 in SK-ES-1 cells. Based on data from Fig. 1B, CI values were calculated with the Chou-Talalay method. CI values in bold indicate a synergistic interaction (CI values > 0.8 were not considered synergistic). Additional file S6: Table S6: CI values for triapine plus ZN-c3 in A673 cells. Based on data from Fig. 1B, CI values were calculated with the Chou-Talalay method. CI values in bold indicate a synergistic interaction (CI values > 0.8 were not considered synergistic). Additional file S9: Table S7: CI values for olaparib plus adavosertib in WE-68 cells. Based on data from Fig. S1, CI values were calculated with the Chou-Talalay method. CI values in bold indicate a synergistic interaction (CI values > 0.8 were not considered synergistic). Additional file S10: Table S8: CI values for veliparib plus adavosertib in WE-68 cells. Based on data from Fig. S1, CI values were calculated with the Chou-Talalay method. CI values in bold indicate a synergistic interaction (CI values > 0.8 were not considered synergistic). Additional file S11: Table S9: CI values for olaparib plus adavosertib in SK-ES-1 cells. Based on data from Fig. S1, CI values were calculated with the Chou-Talalay method. CI values in bold indicate a synergistic interaction (CI values > 0.8 were not considered synergistic). Additional file S12: Table S10: CI values for veliparib plus adavosertib in SK-ES-1 cells. Based on data from Fig. S1, CI values were calculated with the Chou-Talalay method. CI values in bold indicate a synergistic interaction (CI values > 0.8 were not considered synergistic). Additional file S13: Table S11: Statistical analysis for triapine-adavosertib-induced cell death. Based on data from Fig. 1A, p values were calculated with the Kruskal-Wallis test followed by the Dunn’s test. Additional file S14: Table S12: Statistical analysis for triapine-ZN-c3-induced cell death. Based on data from Fig. 1B, p values were calculated with the Kruskal-Wallis test followed by the Dunn’s test. Additional file S15: Table S13: Statistical analysis for triapine-adavosertib-induced Δψm loss. Based on data from Fig. 3A, p values were calculated with the Kruskal-Wallis test followed by the Dunn’s test. Additional file S16: Table S14: Statistical analysis for triapine-ZN-c3-induced Δψm loss. Based on data from Fig. 4A, p values were calculated with the Kruskal-Wallis test followed by the Dunn’s test. Additional file S17: Table S15: Statistical analysis for triapine-adavosertib-induced caspase 3/7 activity. Based on data from Fig. 3B, p values were calculated with the Kruskal-Wallis test followed by the Dunn’s test. Additional file S18: Table S16: Statistical analysis for triapine-ZN-c3-induced caspase 3/7 activity. Based on data from Fig. 4B, p values were calculated with the Kruskal-Wallis test followed by the Dunn’s test